CTX-130

N/A

Report date: 2025/01/09 20:00:05

Base Information

Drug NameCTX-130

Drug Alias NameCTX-130

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD70

TargetsCD70 antigen

Therapy Area/IndicationsCarcinoma, Renal CellLymphoma, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesNetherlands +[4]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCrispr Therapeutics Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCrispr Therapeutics Ag

Active IndicationsN/A

Inactive IndicationsCarcinoma, Renal CellLymphoma, T-Cell

Other Information

ATC CodeN/A